Seagen and Genmab: Breakthrough Cervical Cancer Trial Outcome
- September 04th, 2023
- 631 views
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have reported a significant breakthrough in the Phase 3 innovaTV 301 global trial for recurrent or metastatic cervical cancer. Patients treated with TIVDAK (tisotumab vedotin-tftv) showed an improvement in overall survival (OS) compared to those receiving chemotherapy alone. An Independent Data Monitoring Committee found that OS exceeded the pre-specified efficacy threshold during interim analysis.
Additionally, key secondary endpoints, including progression-free survival and objective response rate, displayed statistically significant results. The safety profile of TIVDAK in the trial remained consistent with known information, with no new safety concerns.
On Friday, $SGEN closed at $207.91, gaining $1.84 (+0.89%), while $GMAB closed at $38.38, up $0.09 (+0.24%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Herbal Works Celebrates Successful Earth Day Grand Opening and Extends Exclusive Grand Opening Offer
April 27th, 2026FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
April 24th, 2026April 23rd, 2026
Member Login